Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.
GSK announced the granting of awards under the 2017 Deferred Annual Bonus Plan to several key executives, including the CEO and CFO, requiring them to defer portions of their bonuses into Ordinary Shares or American Depositary Shares for three years. This move, aligned with shareholder-approved remuneration policies, aims to reinforce commitment to the company’s long-term performance and align the interests of its executives with those of the stakeholders.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a leading company in the pharmaceutical industry, primarily focused on developing and producing a wide range of medicines, vaccines, and healthcare products. The company operates globally and is known for its innovative approaches to healthcare solutions.
YTD Price Performance: 6.76%
Average Trading Volume: 7,365,639
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £58.9B
For an in-depth examination of GSK stock, go to TipRanks’ Stock Analysis page.
